APA

Luetkemeyer A. F., Rosenkranz S. L., Lu D., Grinsztejn B., Sanchez J., Ssemmanda M., Sanne I., McIlleron H., Havlir D. V. & Haas D. W. (20160222). Combined effect of CYP2B6 and NAT2 genotype on plasma efavirenz exposure during rifampin-based antituberculosis therapy in the STRIDE study. : Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Chicago

Luetkemeyer Anne F, Rosenkranz Susan L, Lu Darlene, Grinsztejn Beatriz, Sanchez Jorge, Ssemmanda Michael, Sanne Ian, McIlleron Helen, Havlir Diane V and Haas David W. 20160222. Combined effect of CYP2B6 and NAT2 genotype on plasma efavirenz exposure during rifampin-based antituberculosis therapy in the STRIDE study. : Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Harvard

Luetkemeyer A. F., Rosenkranz S. L., Lu D., Grinsztejn B., Sanchez J., Ssemmanda M., Sanne I., McIlleron H., Havlir D. V. and Haas D. W. (20160222). Combined effect of CYP2B6 and NAT2 genotype on plasma efavirenz exposure during rifampin-based antituberculosis therapy in the STRIDE study. : Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

MLA

Luetkemeyer Anne F, Rosenkranz Susan L, Lu Darlene, Grinsztejn Beatriz, Sanchez Jorge, Ssemmanda Michael, Sanne Ian, McIlleron Helen, Havlir Diane V and Haas David W. Combined effect of CYP2B6 and NAT2 genotype on plasma efavirenz exposure during rifampin-based antituberculosis therapy in the STRIDE study. : Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 20160222.